Stockreport

ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB

ABLYNX NV ADS  (ABLX) 
US:NASDAQ Investor Relations: ablynx.com/investors/overview
PDF Comparable pharmacokinetics (PK) observed in Japanese and Caucasian healthy volunteers Caplacizumab was well-tolerated in all groups GHENT, Belgium, 21 December [Read more]